Overview
Dementia is not fully preventable, and developing it is never a personal failure. Age, genetics, medical illness, social conditions, and biological processes that are not yet understood all contribute. At the same time, the evidence now supports a more hopeful and precise message: some dementia risk can be reduced or delayed by addressing health and life-course factors that are potentially modifiable.
The strongest recent evidence comes from two complementary sources. The 2024 Lancet Commission estimated that 14 potentially modifiable factors account for about 45% of dementia at a population level. In 2025, the U.S. POINTER randomized trial showed that a structured two-year program combining physical activity, a healthy dietary pattern, cognitive and social engagement, and cardiovascular monitoring produced a statistically greater improvement in global cognition than a lower-intensity self-guided program.12
The most important conclusions are:
- Risk reduction is real, but it is not a guarantee. The 45% estimate describes populations, not an individual person’s destiny.
- Several useful actions overlap. Treating blood pressure, cholesterol, diabetes, hearing loss, vision loss, smoking, inactivity, and social isolation can improve general health while also addressing dementia risk.
- Multidomain programs appear more useful than a single supplement or one isolated habit. U.S. POINTER and the earlier FINGER trial combined several interventions rather than testing a magic ingredient.23
- The randomized evidence is encouraging but should not be overstated. U.S. POINTER measured cognitive change over two years; it did not prove that the intervention prevents dementia decades later.
- Genetic risk does not make healthy action pointless. In U.S. POINTER, the relative benefit of the structured program did not differ by APOE ε4 carrier status.2
- Earlier action is sensible, but later-life treatment still matters. Blood pressure control, hearing care, physical activity, fall prevention, and social connection remain worthwhile at older ages.
Evidence cutoff: This article reflects publicly available evidence through July 10, 2026. The main Alzheimer’s Association International Conference is scheduled for July 12–15, 2026 in London and online. Findings scheduled for presentation after this cutoff are not treated here as established results.7
What Does “Reducing Risk” Actually Mean?
A risk factor changes probability; it does not determine fate. Some people with many risk factors never develop dementia, while others with excellent health habits do. Dementia also has multiple causes, including Alzheimer’s disease, vascular brain injury, Lewy body disease, frontotemporal degeneration, and mixed pathologies. A strategy that lowers vascular or Alzheimer’s-related risk cannot eliminate every pathway to cognitive impairment.
The Lancet Commission’s 45.3% figure is a population attributable fraction. It estimates the proportion of dementia cases that might theoretically be prevented or delayed if the associations are causal and the listed exposures could be eliminated across a population. It is not the percentage by which a particular person can lower risk, and the individual percentages should not simply be added to create a personalized score.1
The estimate also has limitations: risk factors overlap, some may be consequences as well as causes of early disease, exposure is measured imperfectly, and the evidence base is stronger in some countries and populations than others. The practical value is not a promise of prevention. It is a map of areas where clinical care and public health can plausibly make a difference.
The 14 Potentially Modifiable Factors
| Life stage emphasized by the Commission | Factor | Approximate population-attributable fraction | Practical interpretation |
|---|---|---|---|
| Early life | Less education | 5% | Access to education and lifelong opportunities for cognitive development matter at a population level. |
| Midlife | Hearing loss | 7% | Identify and treat hearing impairment; do not accept avoidable communication loss as normal aging. |
| Midlife | High LDL cholesterol | 7% | Assess cardiovascular risk and treat lipids according to individualized medical guidance. |
| Midlife | Depression | 3% | Evaluate and treat persistent depression; the relationship with dementia is complex and not proof of causation in every individual. |
| Midlife | Traumatic brain injury | 3% | Use seat belts and helmets when appropriate, reduce falls, and address occupational or sports risk. |
| Midlife | Physical inactivity | 2% | Build regular aerobic, strength, balance, and mobility activity appropriate to health and ability. |
| Midlife | Diabetes | 2% | Prevent or manage diabetes and related vascular complications. |
| Midlife | Smoking | 2% | Smoking cessation benefits the brain, heart, lungs, and circulation. |
| Midlife | Hypertension | 2% | Measure and treat blood pressure while avoiding unsafe one-size-fits-all targets. |
| Midlife | Obesity | 1% | Focus on sustainable metabolic health, nutrition, activity, and treatment of related conditions. |
| Midlife | Excessive alcohol use | 1% | Avoid heavy drinking; alcohol should not be started for presumed brain benefit. |
| Later life | Social isolation | 5% | Preserve meaningful relationships, community involvement, and access to communication. |
| Later life | Air pollution | 3% | This is substantially a policy and environmental issue, not solely an individual responsibility. |
| Later life | Untreated vision loss | 2% | Obtain regular eye care and address treatable visual impairment. |
The life-stage labels describe where the Commission found the strongest evidence; they are not deadlines. Treating hypertension, diabetes, sensory loss, depression, smoking, inactivity, or isolation can still be valuable after age 65.1
What Randomized Trials Have Actually Shown
U.S. POINTER: A Modest but Rigorous Cognitive Benefit
U.S. POINTER enrolled 2,111 adults ages 60 to 79 who were at increased risk for cognitive decline. Participants were randomly assigned to one of two active, two-year multidomain programs. Both included physical activity, a MIND-style dietary pattern, cognitive and social engagement, and cardiovascular monitoring. The structured group received more frequent meetings, coaching, accountability, and prespecified activity goals; the self-guided group received education and less intensive support.2
Global cognition improved by 0.243 standard deviations per year in the structured group and 0.213 in the self-guided group. The between-group difference was 0.029 standard deviations per year (95% CI, 0.008–0.050; P=.008). This was statistically significant, but small. The trial therefore supports a structured multidomain approach while leaving open how noticeable the average difference is in daily life and whether it reduces future dementia incidence.2
The structured program’s relative benefit was consistent across prespecified subgroups, including APOE ε4 carriers and noncarriers. That is reassuring, but it does not mean that lifestyle erases genetic risk or that every participant benefited equally.
FINGER: The Earlier Multidomain Precedent
The Finnish FINGER trial randomized 1,260 at-risk older adults to a two-year program of diet, exercise, cognitive training, and vascular-risk monitoring or to general health advice. The intervention group had a greater improvement in a composite cognitive score. FINGER helped establish the model that U.S. POINTER later tested in a more diverse U.S. population.3
SPRINT MIND: Blood Pressure and Cognitive Outcomes
SPRINT MIND studied 9,361 adults with hypertension but without diabetes or prior stroke. Targeting systolic blood pressure below 120 mm Hg, compared with below 140 mm Hg, did not significantly reduce the primary outcome of probable dementia during the trial (hazard ratio 0.83; 95% CI, 0.67–1.04). It did reduce adjudicated mild cognitive impairment and the combined outcome of mild cognitive impairment or probable dementia.4
This supports good blood-pressure care, not a universal instruction that every older adult should pursue the same intensive target. Frailty, falls, orthostatic symptoms, kidney disease, medication burden, and individual cardiovascular risk all matter.
ACHIEVE: Hearing Treatment Was Not a Universal Dementia Intervention
ACHIEVE randomized older adults with hearing loss to a hearing intervention or a successful-aging health-education control. Across the full cohort, the hearing intervention did not significantly slow three-year cognitive decline. In a prespecified subgroup drawn from the higher-risk ARIC cohort, however, cognitive decline was approximately 48% slower with the hearing intervention; no cognitive benefit was found in the healthier community-volunteer subgroup.5
The responsible conclusion is not that hearing aids have been proven to prevent dementia for everyone. It is that treating hearing loss clearly improves communication and function, may reduce cognitive decline in some higher-risk older adults, and is a sensible component of comprehensive care.
A Practical, Evidence-Based Brain-Health Plan
1. Protect Cardiovascular and Metabolic Health
- Know your blood pressure and review the appropriate target with your clinician.
- Assess LDL cholesterol and overall cardiovascular risk rather than treating a laboratory number in isolation.
- Prevent or manage diabetes, smoking, obesity, atrial fibrillation, and other vascular conditions.
- Take prescribed medications consistently and report dizziness, falls, or low blood-pressure symptoms rather than stopping treatment on your own.
Vascular injury and Alzheimer’s pathology often coexist. Preventing stroke and small-vessel brain injury is valuable even when it cannot prevent every form of dementia.
2. Exercise Regularly and Safely
A reasonable goal for many adults is regular moderate aerobic activity together with strength, balance, and flexibility work, adjusted for disability and medical conditions. The important features are consistency, progression, and safety. Someone who is inactive may gain more from a sustainable walking and resistance program than from an ambitious plan that is quickly abandoned.
3. Treat Hearing and Vision Loss
Hearing and vision affect communication, mobility, cognitive load, and social participation. Obtain hearing testing when conversations are becoming difficult, review hearing-aid fit and use, and maintain routine eye care. Sudden hearing or vision loss requires prompt medical assessment.
4. Maintain Social and Cognitive Engagement
Meaningful activity is broader than puzzles. Learning, volunteering, music, reading, work, caregiving, religious or community participation, and regular conversation can all provide cognitive and social stimulation. The goal is sustained engagement that is personally meaningful, not a specific commercial brain-training product.
5. Address Depression, Alcohol, Smoking, and Head Injury
Persistent depression deserves evaluation and treatment for its own sake. Avoid smoking, avoid heavy alcohol use, use appropriate protective equipment, and reduce fall risk through medication review, vision care, balance training, home-safety changes, and treatment of gait disorders.
6. Use a Healthy Dietary Pattern, Not a Miracle Food
U.S. POINTER incorporated a MIND-style dietary pattern, and Mediterranean- and DASH-style eating patterns are reasonable choices for cardiometabolic health. The evidence supports an overall pattern rich in vegetables, fruits, legumes, nuts, whole grains, fish, and unsaturated fats, with less highly processed food, rather than a particular berry, oil, supplement, or restrictive diet as a proven dementia preventive.
7. Take Sleep Problems Seriously—Without Overstating the Evidence
Sleep is important for attention, mood, blood pressure, metabolism, and quality of life. Symptoms of sleep apnea, insomnia, restless legs, or dream-enactment behavior warrant evaluation. However, sleep was not included among the Commission’s final 14 factors, and treating a sleep disorder should not be marketed as a proven guarantee against dementia.1
Family History and Genetics
Most dementia is not caused by a single inherited mutation. APOE ε4 raises the probability of Alzheimer’s disease but does not determine whether or when it will occur. Routine APOE testing in a healthy adult can create uncertainty and is not required to follow a risk-reduction plan. Testing may be appropriate in selected clinical or research contexts, especially when it will change management and counseling is available.
A family with several relatives who developed dementia at unusually young ages may warrant formal genetic counseling for rare autosomal-dominant Alzheimer’s disease. Direct-to-consumer results should not be treated as a diagnosis without clinical confirmation and interpretation.
What Has Not Been Proven
- No vitamin, supplement, nootropic, or commercial infusion has been proven to prevent dementia in the general population. Correct a documented deficiency, but avoid assuming that more is better.
- Routine amyloid blood testing, amyloid PET, or APOE testing is not established as population screening for cognitively healthy adults. A biomarker can identify biology without reliably predicting an individual’s future.
- Anti-amyloid antibodies are not approved for cognitively unimpaired people. Presymptomatic treatment remains a clinical-trial question.
- Commercial cognitive testing or brain imaging cannot guarantee early detection or prevention. Tests should be selected when the result can answer a clinical question or change care.
- No single blood-pressure, cholesterol, exercise, or dietary target fits everyone. Risk reduction should be individualized around safety, comorbidities, and patient goals.
When Memory Symptoms Need a Clinical Evaluation
Risk reduction is not a substitute for diagnosis. Seek evaluation when there is progressive repetition, missed medications or bills, difficulty navigating familiar places, loss of work efficiency, language or visuospatial change, unsafe driving, personality change, or decline in previously independent daily activities. Depression, sleep disorders, medications, thyroid disease, vitamin deficiency, hearing loss, stroke, seizures, and other conditions can mimic or worsen cognitive symptoms.
A clinical assessment may include a history from the patient and a knowledgeable care partner, neurological examination, cognitive testing, laboratory evaluation, medication and sleep review, assessment of daily function, and brain imaging when appropriate. Biomarkers are added selectively when they can clarify cause or guide treatment.6
The Bottom Line
Dementia risk is not completely controllable, but it is not completely fixed. The best-supported strategy is a multidomain, medically supervised approach: protect cardiovascular health, remain physically active, treat hearing and vision loss, avoid smoking and heavy alcohol use, reduce head injury, address depression, and stay socially and cognitively engaged. The average effects are likely to be gradual and modest, but they apply to health well beyond dementia.
At Los Altos Neurology, brain-health counseling begins with the person’s history, current function, medical risks, sensory health, sleep, mood, medications, and goals. Cognitive testing, laboratory studies, imaging, or biomarkers are used when clinically appropriate—not as automatic screening packages or guarantees of prevention. The aim is to identify realistic, high-value actions while remaining honest about what medicine can and cannot predict.
References
- Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572–628. doi:10.1016/S0140-6736(24)01296-0.
- Baker LD, Espeland MA, Whitmer RA, et al. Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The U.S. POINTER Randomized Clinical Trial. JAMA. 2025;334(8):681–691. doi:10.1001/jama.2025.12923.
- Ngandu T, Lehtisalo J, Solomon A, et al. A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER). Lancet. 2015;385(9984):2255–2263. doi:10.1016/S0140-6736(15)60461-5.
- Williamson JD, Pajewski NM, Auchus AP, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321(6):553–561. doi:10.1001/jama.2018.21442.
- Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE). Lancet. 2023;402(10404):786–797. doi:10.1016/S0140-6736(23)01406-X.
- Alzheimer’s Association. Clinical practice guidance for evaluating suspected Alzheimer’s disease and related disorders. 2024.
- Alzheimer’s Association. Alzheimer’s Association International Conference 2026. July 12–15, 2026, London and online.
Medical disclaimer. This article is provided for general educational and informational purposes only. It does not constitute individualized medical advice, diagnosis, treatment, a recommendation for any specific test or therapy, or informed consent. Medical information changes over time, and this article may not reflect developments occurring after its stated review date or apply to your individual circumstances. Do not disregard or delay professional medical advice, or start, stop, or change any medication or treatment, based on this article. Discuss personal medical decisions with a qualified healthcare professional who can evaluate your individual history and circumstances. Accessing or using this website does not, by itself, create a physician–patient relationship with Los Altos Neurology or any of its clinicians. Do not use this website for urgent or emergency medical concerns; call 911 or seek immediate emergency care. Although Los Altos Neurology makes reasonable efforts to provide accurate and current information, it does not guarantee that all content is complete, current, or applicable to every individual. See our full Medical Disclaimer.